Cantor Fitzgerald analyst Louise Chen reiterated the firm’s Overweight rating or $15 price target on shares of Scynexis (SCYX) following the "good" Q4 and announcement of a deal with GSK (GSK). The firm sees "lots to like" and continues to think that the peak sales potential of ibrexafungerp for the treatment of fungal infections is underappreciated and also expects upwards earnings estimate revisions to drive Scynexis shares higher as earnings visibility for the company improves, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SCYX:
- SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Scynexis reports FY22 EPS ($1.47), consensus ($1.52)
- Scynexis price target raised to $10 from $7 at Maxim
- SCYNEXIS Skyrockets on Teaming Up With GSK for Fungal Treatment
- Scynexis, GSK announce exclusive agreement to commercialize, develop Brexafemme